FUL Stock Analysis: H Fuller | NYSE

Specialty Chemicals | NYSE, USA | Market Cap: 2.638m USD | 12M Return: -15.1% | US3596941068 | Charts, Fundamentals & Technical Analysis

Adhesives, Sealants, Coatings, Tapes
Total Rating 28
Safety 68
Buy Signal -1.05
Specialty Chemicals
Sub-Industry Rotation: -2.9
Market Cap: 2.64B
Avg Turnover: 26.4M
Risk 3d forecast
Volatility30.8%
VaR 5th Pctl5.24%
VaR vs Median3.39%
Reward TTM
Sharpe Ratio-0.42
Rel. Str. IBD14.5
Rel. Str. Peer Group11.5 pctl
Character TTM
Beta0.794
Beta Downside0.947
Hurst Exponent0.611
Choppyness58.6%
Drawdowns 3y
Max DD44.40%
CAGR/Max DD-0.32
CAGR/Mean DD-0.63
EPS (Earnings per Share) EPS (Earnings per Share) of FUL over the last years for every Quarter: "2021-11": 1.09, "2022-02": 0.8, "2022-05": 1.11, "2022-08": 1.06, "2022-11": 1.04, "2023-02": 0.55, "2023-05": 0.93, "2023-08": 1.06, "2023-11": 1.32, "2024-02": 0.67, "2024-05": 1.12, "2024-08": 1.13, "2024-11": 0.92, "2025-02": 0.54, "2025-05": 1.18, "2025-08": 1.26, "2025-11": 1.28, "2026-02": 0.57, "2026-05": 1.41, "2026-08": 1.52,
EPS CAGR: 5.43%
EPS Trend: 61.4%
Last SUE: 0.52
Qual. Beats: 0
Revenue Revenue of FUL over the last years for every Quarter: 2021-11: 897.424, 2022-02: 856.482, 2022-05: 993.258, 2022-08: 941.23, 2022-11: 958.213, 2023-02: 809.183, 2023-05: 898.239, 2023-08: 900.634, 2023-11: 902.879, 2024-02: 810.419, 2024-05: 917.107, 2024-08: 917.927, 2024-11: 923.284, 2025-02: 788.663, 2025-05: 898.095, 2025-08: 892.043, 2025-11: 894.788, 2026-02: 770.844, 2026-05: 950.271, 2026-08: 938.175,
Rev. CAGR: -0.27%
Rev. Trend: -26.1%
Last SUE: -0.02
Qual. Beats: 0

Warnings

Fakeout
Below Avwap Earnings
Below Sma 200d

Tailwinds

Seasonal Tailwind

Seasonality 11.9 years of data, until 10/2026

Jan -2.6% 21
Feb +2.0% 4
Mar -0.2% 0
Apr -0.2% 0
May +1.3% 14
Jun -0.6% 0
Jul +1.3% 28
Aug -0.1% 14
Sep -5.4% 47
Oct -1.4% 4
Nov ★ +7.7% 64
Dec -3.5% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.

Description: FUL H Fuller
>H.B. Fuller Company (NYSE: FUL) is a specialty chemicals manufacturer that formulates, produces, and sells adhesives, sealants, coatings, polymers, tapes, encapsulants, and additives. Founded in 1887 and headquartered in Saint Paul, Minnesota, the company operates as a B2B formulator, supplying formulated chemical products that are typically specified into customers manufacturing processes rather than sold as off-the-shelf commodities.

The business is organized into three segments. The Hygiene, Health and Consumable Adhesives segment supplies specialty industrial adhesives (thermoplastic, thermoset, reactive, water-based, and solvent-based) for packaging, converting, nonwoven and hygiene, and medical and beauty applications. The Engineering Adhesives segment offers high-performance bonding products for durable assembly, performance wood and textile, transportation, electronics, clean energy, aerospace and defense, appliance, heavy machinery, and insulating glass markets. The Building Adhesive Solutions segment provides products for commercial roofing, HVAC and insulation applications, as well as caulks and sealants for the consumer and professional trade.

H.B. Fuller distributes its products through direct sales, distributors, and retailers across North America, Latin America, Europe, India, the Middle East, Africa, and the Asia Pacific. The breadth of end markets served is a defining feature of the specialty chemicals business model, with revenue tied to the production volumes and product cycles of a wide range of industrial customers.

Headlines to Watch Out For
  • Hygiene segment margins expand on price and mix shift
  • Engineering adhesives gain from EV and clean energy growth
  • Construction adhesives face U.S. housing demand headwinds
Piotroski VR-10 (Strict) 4.0
Net Income: 197.8m TTM > 0 and > 6% of Revenue
FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.51 > 1.0
NWC/Revenue: 18.79% < 20% (prev 17.89%; Δ 0.90% < -1%)
CFO/TA 0.05 > 3% & CFO 289.4m > Net Income 197.8m
Net Debt (2.02b) to EBITDA (586.3m): 3.44 < 3
Current Ratio: 1.82 > 1.5 & < 3
Outstanding Shares: last quarter (54.9m) vs 12m ago -0.86% < -2%
Gross Margin: 32.79% > 18% (prev 30.69%; Δ 2.10% > 0.5%)
Asset Turnover: 67.10% > 50% (prev 67.79%; Δ -0.69% > 0%)
Interest Coverage Ratio: 2.89 > 6 (EBIT TTM 402.3m / Interest Expense TTM 139.4m)
Altman Z'' 3.31
A: 0.12 (Total Current Assets 1.49b - Total Current Liabilities 818.1m) / Total Assets 5.43b
B: 0.40 (Retained Earnings 2.15b / Total Assets 5.43b)
C: 0.08 (EBIT TTM 402.3m / Avg Total Assets 5.30b)
D: 0.67 (Book Value of Equity 2.17b / Total Liabilities 3.26b)
Altman-Z'' = 3.31 = A
Beneish M -2.70
DSRI: 1.13 (Receivables 648.0m/563.6m, Revenue 3.55b/3.50b)
GMI: 0.94 (GM 30.69% / 32.79%)
AQI: 1.44 (AQ_t 0.55 / AQ_t-1 0.38)
SGI: 1.01 (Revenue 3.55b / 3.50b)
TATA: -0.02 (NI 197.8m - CFO 289.4m) / TA 5.43b)
Beneish M = -2.70 (Cap -4..+1) = A
What is the price of FUL shares?

As of November 22, 2026, the stock is trading at USD 46.24 with a total of 485,050 shares traded. Over the past week, the price has changed by -6.19%, over one month by -8.56%, over three months by -21.46% and over the past year by -15.13%.

Current recommended Stop Loss: 44.10 (which is 4.6% or 1.4 ATR below the current price).

Is FUL a buy, sell or hold?

H Fuller has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy FUL.

  • StrongBuy: 5
  • Buy: 1
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the FUL price?
Analysts Target Price 66.3 43.4%
H Fuller (FUL) - Fundamental Data Overview as of 18 November 2026
Market Cap USD = 2.64b (2.64b USD * 1.0 USD.USD)
P/E Trailing = 13.649
P/E Forward = 9.3023
P/S = 0.7421
P/B = 1.2238
P/EG = 2.2026
Revenue TTM = 3.55b USD
EBIT TTM = 402.3m USD
EBITDA TTM = 586.3m USD
Long Term Debt = 2.05b USD (from longTermDebt, last quarter)
 Short Term Debt = unknown (none)
 Debt = 2.11b USD (from shortLongTermDebtTotal, last quarter) + Leases 59.1m
Net Debt = 2.02b USD (calculated: Debt 2.11b - CCE 97.2m)
Enterprise Value = 4.65b USD (2.64b + Debt 2.11b - CCE 97.2m)
Interest Coverage Ratio = 2.89 (Ebit TTM 402.3m / Interest Expense TTM 139.4m)
EV/FCF = 46.53x (Enterprise Value 4.65b / FCF TTM 100.0m)
FCF Yield = 2.15% (FCF TTM 100.0m / Enterprise Value 4.65b)
FCF Margin = 2.81% (FCF TTM 100.0m / Revenue TTM 3.55b)
Net Margin = 5.56% (Net Income TTM 197.8m / Revenue TTM 3.55b)
Gross Margin = 32.79% ((Revenue TTM 3.55b - Cost of Revenue TTM 2.39b) / Revenue TTM)
Gross Margin QoQ = 33.22% (prev 33.91%)
Tobins Q-Ratio = 0.86 (Enterprise Value 4.65b / Total Assets 5.43b)
Interest Expense / Debt = 6.59% (Interest Expense 139.4m / Debt 2.11b)
Taxrate = 26.03% (69.6m / 267.4m)
NOPAT = 297.6m (EBIT 402.3m * (1 - 26.03%))
Current Ratio = 1.82 (Total Current Assets 1.49b / Total Current Liabilities 818.1m)
Debt / Equity = 0.97 (Debt 2.11b / totalStockholderEquity, last quarter 2.17b)
Debt / EBITDA = 3.44 (Net Debt 2.02b / EBITDA 586.3m)
Debt / FCF = 20.16 (Net Debt 2.02b / FCF TTM 100.0m)
Total Stockholder Equity = 2.08b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.73% (Net Income 197.8m / Total Assets 5.43b)
RoE = 9.51% (Net Income TTM 197.8m / Total Stockholder Equity 2.08b)
RoCE = 9.73% (EBIT 402.3m / Capital Employed (Equity 2.08b + L.T.Debt 2.05b))
RoIC = 6.60% (NOPAT 297.6m / Invested Capital 4.51b)
WACC = 6.78% (E(2.64b)/V(4.75b) * Re(8.31%) + D(2.11b)/V(4.75b) * Rd(6.59%) * (1-Tc(0.26)))
Discount Rate = 8.31% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -86.74 | Cagr: -1.37%
[DCF] Terminal Value 73.10% ; FCFF base≈108.6m ; Y1≈95.2m ; Y5≈76.9m
 [DCF] Fair Price = N/A (negative equity: EV 1.23b - Net Debt 2.02b = -781.7m; debt exceeds intrinsic value)
 EPS Correlation: 61.39 | EPS CAGR: 5.43% | SUE: 0.52 | # QB: 0
Revenue Correlation: -26.08 | Revenue CAGR: -0.27% | SUE: -0.02 | # QB: 0
EPS current Quarter (2027-02-28): EPS=0.71 | Chg30d=-6.73% | Revisions=-25% | Analysts=3
EPS current Year (2026-11-30): EPS=4.85 | Chg30d=-0.42% | Revisions=+10% | GrowthEPS=+14.4% | GrowthRev=+3.8%
EPS next Year (2027-11-30): EPS=5.15 | Chg30d=-1.88% | Revisions=-30% | GrowthEPS=+6.2% | GrowthRev=+7.2%
[Analyst] Revisions Ratio: -17% (up=6, down=9)